COPD und Begleiterkrankungen Ergebnisse des Expertentreffens Luftschlösser 2008 Tremsbüttel, 28.–29. November 2008 Sponsor: Boehringer Ingelheim Pharma GmbH&Co KG
暂无分享,去创建一个
H. Magnussen | A. Gillissen | H. Teschler | H. Worth | C. Vogelmeier | G. Schultze-Werninghaus | G. Steinkamp | H. Morr | M. Pfeifer | J. Lorenz | R. Dierkesmann | T. Köhnlein | C. Taube
[1] M. Padeletti,et al. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. , 2007, Journal of the American College of Cardiology.
[2] R. Abbott,et al. Association of snoring with chronic bronchitis. , 2008, Archives of internal medicine.
[3] S. Sidney,et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. , 2005, Chest.
[4] J. Barberà,et al. Effects of endurance training on skeletal muscle bioenergetics in chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.
[5] D. Sin,et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.
[6] E. Wouters,et al. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.
[7] G. Donaldson,et al. Inflammatory changes, recovery and recurrence at COPD exacerbation , 2007, European Respiratory Journal.
[8] L. Fabbri,et al. Airway eosinophilia in chronic bronchitis during exacerbations. , 1994, American journal of respiratory and critical care medicine.
[9] T. Pietras,et al. Increased content of thiobarbituric acid-reactive substances and hydrogen peroxide in the expired breath condensate of patients with stable chronic obstructive pulmonary disease: no significant effect of cigarette smoking. , 1999, Respiratory medicine.
[10] G. Rohde,et al. Inflammatory Response in Acute Viral Exacerbations of COPD , 2008, Infection.
[11] E. Salpeter,et al. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. , 2004, Chest.
[12] P. Barnes,et al. Exhaled biomarkers. , 2006, Chest.
[13] H. Worth,et al. COPD und Psyche - ein Überblick , 2005 .
[14] W. Maziak,et al. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.
[15] P. Gibson,et al. Eosinophilic bronchitis: clinical manifestations and implications for treatment , 2002, Thorax.
[16] R. Stockley,et al. Rate of progression of lung function impairment in α1-antitrypsin deficiency , 2009, European Respiratory Journal.
[17] S. Sethi. Infectious etiology of acute exacerbations of chronic bronchitis. , 2000, Chest.
[18] T. Gislason,et al. Mortality in COPD patients discharged from hospital: the role of treatment and co-morbidity , 2006, Respiratory research.
[19] B E Ainsworth,et al. Compendium of physical activities: an update of activity codes and MET intensities. , 2000, Medicine and science in sports and exercise.
[20] Marta Benet,et al. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort study. , 2007, American journal of respiratory and critical care medicine.
[21] Ciro Casanova,et al. Distance and oxygen desaturation during the 6-min walk test as predictors of long-term mortality in patients with COPD. , 2008, Chest.
[22] K. Kostikas,et al. VEGF, TNF-alpha and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer. , 2009, Lung cancer.
[23] A. Vgontzas. Does obesity play a major role in the pathogenesis of sleep apnoea and its associated manifestations via inflammation, visceral adiposity, and insulin resistance? , 2008, Archives of physiology and biochemistry.
[24] J. Vestbo,et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.
[25] R. Cook,et al. Changing pattern of sputum cell counts during successive exacerbations of airway disease. , 2007, Respiratory medicine.
[26] F. Maltais,et al. Aerobic and strength training in patients with chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.
[27] H. Magnussen,et al. In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. , 2001, Respiratory medicine.
[28] W. MacNee,et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) , 2008, European Respiratory Journal.
[29] P. Jones,et al. Outcomes and markers in the assessment of chronic obstructive pulmonary disease , 2006, European Respiratory Journal.
[30] K. Davis,et al. Trends and Cardiovascular Co-morbidities of COPD Patients in the Veterans Administration Medical System, 1991–1999 , 2005, COPD.
[31] M. Etminan,et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. , 2006, Journal of the American College of Cardiology.
[32] F. Rutten,et al. Comparison of B‐type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease , 2007, European journal of heart failure.
[33] P. Jones,et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease , 2006, Thorax.
[34] R. Henry,et al. Reduced mechanical efficiency in chronic obstructive pulmonary disease but normal peak VO2 with small muscle mass exercise. , 2004, American journal of respiratory and critical care medicine.
[35] T. Seemungal,et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease , 2002, Thorax.
[36] M. Decramer,et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.
[37] R. Sakalauskas,et al. Serum and bronchial lavage fluid concentrations of IL-8, SLPI, sCD14 and sICAM-1 in patients with COPD and asthma. , 2007, Respiratory medicine.
[38] W. Bailey,et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. , 1995, JAMA.
[39] P. Paré,et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. , 2007, American journal of respiratory and critical care medicine.
[40] P. Barnes,et al. Clinical aspects of exhaled nitric oxide. , 2000, The European respiratory journal.
[41] D. Sin,et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. , 2004, American journal of respiratory and critical care medicine.
[42] N. Snell,et al. The clinical utility of biomarkers in asthma and COPD. , 2008, Current opinion in pharmacology.
[43] R. Rogers,et al. Oxygen consumption of the respiratory muscles in normal and in malnourished patients with chronic obstructive pulmonary disease. , 1989, The American review of respiratory disease.
[44] Ciro Casanova,et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.
[45] S. Quintana,et al. Mortality after hospitalization for COPD. , 2002, Chest.
[46] Fernando Holguin,et al. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. , 2005, Chest.
[47] Robert Wise,et al. Predictors of mortality in patients with emphysema and severe airflow obstruction. , 2006, American journal of respiratory and critical care medicine.
[48] P. Hirth,et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. , 2000, The Journal of clinical investigation.
[49] Emiel F M Wouters,et al. Systemic inflammation in chronic obstructive pulmonary disease: the role of exacerbations. , 2007, Proceedings of the American Thoracic Society.
[50] B. Celli,et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. , 2005, American journal of respiratory and critical care medicine.
[51] B. Celli,et al. The 6‐min walk distance: change over time and value as a predictor of survival in severe COPD , 2004, European Respiratory Journal.
[52] W. Bailey,et al. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. , 2008, Thorax.
[53] C. Pichard,et al. Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease. A prospective, randomized, controlled study. , 1997, American journal of respiratory and critical care medicine.
[54] K. Schmid,et al. Bronchoalveoläre Lavage , 2007, Der Pathologe.
[55] B. Celli,et al. Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD. , 2007, Chest.
[56] M. Knuiman,et al. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. , 2004, Diabetes care.
[57] V. Tirlapur. Nocturnal deaths among patients with chronic bronchitis and emphysema. , 1984, British medical journal.
[58] X. Busquets,et al. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.
[59] T. Seemungal,et al. Airway and Systemic Inflammation and Decline in Lung Function in Patients With COPD , 2005, Chest.
[60] R. Jörres. Modelling the production of nitric oxide within the human airways. , 2000, The European respiratory journal.
[61] P. Schnohr,et al. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study , 2006, Thorax.
[62] P. Barnes,et al. Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. , 2003, Chest.
[63] Urs Frey,et al. Complexity of chronic asthma and chronic obstructive pulmonary disease: implications for risk assessment, and disease progression and control , 2008, The Lancet.
[64] J. Vestbo,et al. COPD-related morbidity and mortality after smoking cessation: status of the evidence , 2008, European Respiratory Journal.
[65] R. Peto,et al. The natural history of chronic airflow obstruction. , 1977, British medical journal.
[66] R. Pauwels,et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.
[67] E. Wouters,et al. Nutritional abnormalities and supplementation in chronic obstructive pulmonary disease. , 2000, Clinics in chest medicine.
[68] D. Postma,et al. Increased systemic inflammation is a risk factor for COPD exacerbations. , 2008, Chest.
[69] Shing M. Lee,et al. Hemodynamic characterization of patients with severe emphysema. , 2002, American journal of respiratory and critical care medicine.
[70] G. Washko,et al. The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. , 2008, American journal of respiratory and critical care medicine.
[71] H. Krumholz,et al. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. , 2001, Journal of the American College of Cardiology.
[72] J. Soriano,et al. C-reactive protein in patients with COPD, control smokers and non-smokers , 2005, Thorax.
[73] B. M. Lewis,et al. THE NATURAL HISTORY OF EMPHYSEMA. , 1964, Geriatrics.
[74] D. Mannino,et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD , 2008, European Respiratory Journal.
[75] Samia Mora,et al. Physical Activity and Reduced Risk of Cardiovascular Events: Potential Mediating Mechanisms , 2007, Circulation.
[76] K. P. Van de Woestijne,et al. Weight changes in the terminal stages of chronic obstructive pulmonary disease. Relation to respiratory function and prognosis. , 1967, The American review of respiratory disease.
[77] B. Gersh,et al. Time to Presentation With Acute Myocardial Infarction in the Elderly: Associations With Race, Sex, and Socioeconomic Characteristics , 2000, Circulation.
[78] K. Lam,et al. Obstructive sleep apnea is independently associated with insulin resistance. , 2002, American journal of respiratory and critical care medicine.
[79] S. Jann,et al. Peripheral neuropathy in chronic respiratory insufficiency. , 1998, Journal of the peripheral nervous system : JPNS.
[80] D. Sin,et al. Systemic inflammation and mortality in chronic obstructive pulmonary disease. , 2007, Canadian journal of physiology and pharmacology.
[81] Bartolome Celli,et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.
[82] A. Pickard,et al. Risk for Death Associated with Medications for Recently Diagnosed Chronic Obstructive Pulmonary Disease , 2008, Annals of Internal Medicine.
[83] K. Tatara,et al. Cigarette Smoking and Risk for Impaired Fasting Glucose and Type 2 Diabetes in Middle-Aged Japanese Men , 2000, Annals of Internal Medicine.
[84] B. Celli,et al. The modified BODE index: validation with mortality in COPD , 2008, European Respiratory Journal.
[85] J. Wedzicha,et al. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. , 2006, American journal of respiratory and critical care medicine.
[86] I. Pavord,et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. , 2006, American journal of respiratory and critical care medicine.
[87] H. Magnussen,et al. Physical Activity in Patients with Chronic Obstructive Pulmonary Disease. , 2009, ATS 2009.
[88] B. Celli,et al. Exacerbations of chronic obstructive pulmonary disease , 2007, European Respiratory Journal.
[89] N. Anthonisen,et al. Mortality in COPD: role of comorbidities , 2006, European Respiratory Journal.
[90] E. Wouters,et al. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. , 1995, American journal of respiratory and critical care medicine.
[91] S. Redline,et al. Sleep-disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study. , 2004, American journal of epidemiology.
[92] F. Maltais,et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.
[93] P. Ponikowski,et al. ESPEN Guidelines on Enteral Nutrition: Cardiology and pulmonology. , 2006, Clinical nutrition.
[94] Thierry Troosters,et al. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. , 2005, American journal of respiratory and critical care medicine.
[95] W. Bailey,et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. , 2000, American journal of respiratory and critical care medicine.
[96] S. Bojesen,et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.
[97] E. Wouters,et al. Chronic obstructive pulmonary disease • 5: Systemic effects of COPD , 2002, Thorax.
[98] C. Özge,et al. Cranial optic nerve involvements in patients with severe COPD , 2005, Respirology.
[99] C. Y. Wang,et al. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. , 2000, Science.
[100] A. Dirksen,et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in α1-antitrypsin deficiency , 2009, European Respiratory Journal.
[101] G. Folkerts,et al. Cells, mediators and Toll-like receptors in COPD. , 2008, European journal of pharmacology.
[102] F. Blasi,et al. Anxiety and depression in COPD patients: The roles of gender and disease severity. , 2006, Respiratory medicine.
[103] S. Rennard,et al. What have we learned from large drug treatment trials in COPD? , 2007, The Lancet.
[104] F. Maltais,et al. Metabolic and inflammatory profile in obese patients with chronic obstructive pulmonary disease , 2008, Chronic respiratory disease.
[105] P. Barnes,et al. Increased levels of the chemokines GROα and MCP-1 in sputum samples from patients with COPD , 2002, Thorax.
[106] J. Liao,et al. Genetically elevated C-reactive protein and ischemic vascular disease , 2009, Current atherosclerosis reports.
[107] D. Blumenthal,et al. Mortality Rate in Veterans with Multiple Chronic Conditions , 2007, Journal of General Internal Medicine.
[108] C. Furberg,et al. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. , 2008, JAMA.
[109] D A Lynch,et al. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. , 2001, American journal of respiratory and critical care medicine.
[110] M. Martínez-García,et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease , 2005, Thorax.
[111] H. Magnussen,et al. Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. , 2008, American journal of respiratory and critical care medicine.
[112] H. Coxson,et al. Antielastin autoimmunity in tobacco smoking–induced emphysema , 2007, Nature Medicine.
[113] S. Zakynthinos,et al. Effects of rehabilitative exercise on peripheral muscle TNF&agr;, IL-6, IGF-I and MyoD expression in patients with COPD , 2007, Thorax.
[114] Y. Lacasse,et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.
[115] F. Hargreave,et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. , 1998, American journal of respiratory and critical care medicine.